WeVote
Log In

Bill

Bill

HB 236

AN ACT relating to coverage for epinephrine devices.

2025 Regular Session

Kentucky bill requiring health insurance plans to cover epinephrine auto-injectors for severe allergy patients, removing cost barriers to emergency lifesaving medication access.

to Appropriations & Revenue (S)
#actuarialanalysis #childrenandminors #drugsandmedicines #education #higher #effectivedates #delayed #healthbenefitplanmandate #insurance #health #localmandate #medicaid #stateagencies #stateemployeehealthplanmandate #stateemployees
0
WeVote Research Nonpartisan
Bill Summary · HB 236

Legislative bill overview

HB 236 mandates insurance coverage for epinephrine auto-injectors (EpiPens) in Kentucky, ensuring that health insurance plans must cover these life-saving devices for individuals with severe allergies. The bill passed the House unanimously and is currently under Senate review in the Appropriations & Revenue Committee.

Why is this important

Epinephrine auto-injectors are critical emergency medications for people with anaphylaxis risk, and high out-of-pocket costs can prevent patients from obtaining them, creating life-threatening gaps in access. This legislation addresses a public health concern by removing financial barriers to a device that can mean the difference between life and death during severe allergic reactions.

Potential points of contention

  • Insurance cost pass-through: Insurers may increase premiums or reduce coverage in other areas to offset the mandated EpiPen coverage costs
  • Scope ambiguity: The bill may lack clear definition of which epinephrine devices qualify, how many can be dispensed, or coverage frequency limits
  • Generic vs. brand-name: Uncertainty about whether coverage extends equally to generic epinephrine alternatives versus brand-name products, affecting pharmaceutical market dynamics

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.